Search

Your search keyword '"Stockerl-Goldstein KE"' showing total 64 results

Search Constraints

Start Over You searched for: Author "Stockerl-Goldstein KE" Remove constraint Author: "Stockerl-Goldstein KE"
64 results on '"Stockerl-Goldstein KE"'

Search Results

2. The Dynamics of Financial Toxicity in Multiple Myeloma.

3. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19.

4. Machine learning-based scoring models to predict hematopoietic stem cell mobilization in allogeneic donors.

5. Systemic IL-15 promotes allogeneic cell rejection in patients treated with natural killer cell adoptive therapy.

7. Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium.

8. A multi-modal diagnostic model improves detection of cardiac amyloidosis among patients with diagnostic confirmation by cardiac biopsy.

9. Impact of a 40-Gene Targeted Panel Test on Physician Decision Making for Patients With Acute Myeloid Leukemia.

10. Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia.

11. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study.

12. Maintenance therapy following salvage autologous stem cell transplant in patients with multiple myeloma.

13. A Phase I/II Trial of Carfilzomib, Pegylated Liposomal Doxorubicin, and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma.

14. Emerging Therapeutics for the Treatment of Light Chain and Transthyretin Amyloidosis.

15. Results of an early access treatment protocol of daratumumab in United States patients with relapsed or refractory multiple myeloma.

16. Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results.

17. Patterns of infectious complications in acute myeloid leukemia and myelodysplastic syndromes patients treated with 10-day decitabine regimen.

18. TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.

19. Effect of Linezolid on Hematologic Recovery in Newly Diagnosed Acute Myeloid Leukemia Patients Following Induction Chemotherapy.

20. Remobilization of hematopoietic stem cells in healthy donors for allogeneic transplantation.

21. A phase I study of carfilzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia.

22. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.

23. Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients.

24. Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.

25. Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.

26. A phase II study of V-BEAM as conditioning regimen before second auto-SCT for multiple myeloma.

27. A phase I dose escalation study of oral bexarotene in combination with intravenous decitabine in patients with AML.

28. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.

29. Oral valganciclovir versus ganciclovir as delayed pre-emptive therapy for patients after allogeneic hematopoietic stem cell transplant: a pilot trial (04-0274) and review of the literature.

30. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia.

31. Long-term outcome of patients with metastatic breast cancer treated with high-dose chemotherapy and transplantation of purified autologous hematopoietic stem cells.

32. Prognostic significance of FDG-PET in relapsed or refractory classical Hodgkin lymphoma treated with standard salvage chemotherapy and autologous stem cell transplantation.

33. Combination decitabine, arsenic trioxide, and ascorbic acid for the treatment of myelodysplastic syndrome and acute myeloid leukemia: a phase I study.

34. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia.

35. A meta-analysis of patients receiving allogeneic or autologous hematopoietic stem cell transplant in mycosis fungoides and Sézary syndrome.

36. High-dose chemotherapy followed by stem cell rescue for high-risk germ cell tumors: the Stanford experience.

37. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.

38. High-dose carmustine, etoposide, and cyclophosphamide followed by allogeneic hematopoietic cell transplantation for non-Hodgkin lymphoma.

39. Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose.

40. CD34, CD4, and CD8 cell doses do not influence engraftment, graft-versus-host disease, or survival following myeloablative human leukocyte antigen-identical peripheral blood allografting for hematologic malignancies.

41. Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease.

42. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects.

43. Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma.

44. Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma.

45. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients.

46. Rapid engraftment after allogeneic transplantation of density-enriched peripheral blood CD34+ cells in patients with advanced hematologic malignancies.

48. Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease.

49. High-dose therapy and autologous hematopoietic-cell transplantation for follicular lymphoma beyond first remission: the Stanford University experience.

50. Effect of oral glutamine supplementation during bone marrow transplantation.

Catalog

Books, media, physical & digital resources